Neurosurgical patients complicated with hypertension during perioperative period continuous intravenous labetalol hypertension neurosurgery bradycardia hypotension
Conditions
Interventions
Patients who received continuous intravenous labetalol infusion for the treatment of hypertension.
Treatment
Labetalol
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Neurosurgical patients complicated with hypertension who received continuous intravenouslabetalol administration from November 1, 2021 to October 31, 2022
Exclusion criteria
Exclusion criteria: 1. pregnancy 2. patients who received other antihypertensive agents with labetalol 3. brain death 4. patients who received other drugs that affected to hemodynamics 5. patients who were ongoing triple H therapy during subarachnoid hemorrhage 6. patients with neurosurgical that were not related to brain, such as spinal disorders or peripheral nerve diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to achieve blood pressure control time from drug initiation to target blood pressure hour,adverse event Time from drug initiation until termination number of patients with adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| cumulative dose at adverse event Time from drug initiation until event occur milligram,cumulative dose at blood pressure target Time from drug initiation until achievement milligram,factors associating with adverse events Time from drug initiation until event occur association between factor and adverse event | — |
Countries
Thailand
Contacts
Public ContactRaywat Noiphithak
Faculty of Medicine, Thammasat University
Outcome results
None listed